Oral montelukast versus inhaled salmeterol to prevent exercise-induced bonchonconstriction.
Brestel
E P
EP
D000085:Acetates / Q000627:therapeutic use; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000191:economics / Q000627:therapeutic use*; D001250:Asthma, Exercise-Induced / Q000517:prevention & control*; D001993:Bronchodilator Agents / Q000191:economics / Q000627:therapeutic use*; D003521:Cyclopropanes; D004992:Ethics, Medical; D006801:Humans; D011804:Quinolines / Q000627:therapeutic use; D000068299:Salmeterol Xinafoate; D013440:Sulfides
D000085:Acetates; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000068299:Salmeterol Xinafoate; C093875:montelukast; D000420:Albuterol